Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

S Zweegman; CAM Stege; E Haukas; FH Schjesvold; Mark-David Levin; A Waage; RB Leys; SK Klein; D Szatkowski; P Axelsson; TH Do; D Knut-Bojanowska; E van der Spek; A Svirskaite; A Klostergaard; M Salomo; C Blimark; PF Ypma; UH Mellqvist; PJ Poddighe; M Stevens-Kroef; NWCJ v.d. Donk; Pieter Sonneveld; M Hansson; Ronnie van der Holt; N Abildgaard

doi:10.3324/haematol.2019.240374

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

S Zweegman, CAM Stege, E Haukas, FH Schjesvold, Mark-David Levin, A Waage, RB Leys, SK Klein, D Szatkowski, P Axelsson, TH Do, D Knut-Bojanowska, E van der Spek, A Svirskaite, A Klostergaard, M Salomo, C Blimark, PF Ypma, UH Mellqvist, PJ PoddigheM Stevens-Kroef, NWCJ v.d. Donk, Pieter Sonneveld, M Hansson, Ronnie van der Holt, N Abildgaard

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

25 Citations (Scopus)

Original language	English
Pages (from-to)	2879-2882
Number of pages	4
Journal	Haematologica
Volume	105
Issue number	12
DOIs	https://doi.org/10.3324/haematol.2019.240374
Publication status	Published - 2020

Research programs

EMC OR-01

Access to Document

10.3324/haematol.2019.240374

http://hdl.handle.net/1765/133988

Cite this

Zweegman, S., Stege, CAM., Haukas, E., Schjesvold, FH., Levin, M.-D., Waage, A., Leys, RB., Klein, SK., Szatkowski, D., Axelsson, P., Do, TH., Knut-Bojanowska, D., van der Spek, E., Svirskaite, A., Klostergaard, A., Salomo, M., Blimark, C., Ypma, PF., Mellqvist, UH., ... Abildgaard, N. (2020). Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 105(12), 2879-2882. https://doi.org/10.3324/haematol.2019.240374

Zweegman, S ; Stege, CAM ; Haukas, E et al. / Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. In: Haematologica. 2020 ; Vol. 105, No. 12. pp. 2879-2882.

@article{c49e69e51422435f8e4c7e53429efe69,

title = "Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial",

author = "S Zweegman and CAM Stege and E Haukas and FH Schjesvold and Mark-David Levin and A Waage and RB Leys and SK Klein and D Szatkowski and P Axelsson and TH Do and D Knut-Bojanowska and {van der Spek}, E and A Svirskaite and A Klostergaard and M Salomo and C Blimark and PF Ypma and UH Mellqvist and PJ Poddighe and M Stevens-Kroef and {v.d. Donk}, NWCJ and Pieter Sonneveld and M Hansson and {van der Holt}, Ronnie and N Abildgaard",

year = "2020",

doi = "10.3324/haematol.2019.240374",

language = "English",

volume = "105",

pages = "2879--2882",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "12",

}

Zweegman, S, Stege, CAM, Haukas, E, Schjesvold, FH, Levin, M-D, Waage, A, Leys, RB, Klein, SK, Szatkowski, D, Axelsson, P, Do, TH, Knut-Bojanowska, D, van der Spek, E, Svirskaite, A, Klostergaard, A, Salomo, M, Blimark, C, Ypma, PF, Mellqvist, UH, Poddighe, PJ, Stevens-Kroef, M, v.d. Donk, NWCJ, Sonneveld, P, Hansson, M, van der Holt, R & Abildgaard, N 2020, 'Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial', Haematologica, vol. 105, no. 12, pp. 2879-2882. https://doi.org/10.3324/haematol.2019.240374

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. / Zweegman, S; Stege, CAM; Haukas, E et al.
In: Haematologica, Vol. 105, No. 12, 2020, p. 2879-2882.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

AU - Zweegman, S

AU - Stege, CAM

AU - Haukas, E

AU - Schjesvold, FH

AU - Levin, Mark-David

AU - Waage, A

AU - Leys, RB

AU - Klein, SK

AU - Szatkowski, D

AU - Axelsson, P

AU - Do, TH

AU - Knut-Bojanowska, D

AU - van der Spek, E

AU - Svirskaite, A

AU - Klostergaard, A

AU - Salomo, M

AU - Blimark, C

AU - Ypma, PF

AU - Mellqvist, UH

AU - Poddighe, PJ

AU - Stevens-Kroef, M

AU - v.d. Donk, NWCJ

AU - Sonneveld, Pieter

AU - Hansson, M

AU - van der Holt, Ronnie

AU - Abildgaard, N

PY - 2020

Y1 - 2020

U2 - 10.3324/haematol.2019.240374

DO - 10.3324/haematol.2019.240374

M3 - Article

C2 - 33256392

SN - 0390-6078

VL - 105

SP - 2879

EP - 2882

JO - Haematologica

JF - Haematologica

IS - 12

ER -

Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A et al. Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. 2020;105(12):2879-2882. doi: 10.3324/haematol.2019.240374